Paris, France, Cambridge (Massachusetts, United States), May 15, 2023 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at the clinic specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional outcomes of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19 announces today having submitted the authorization application file on the European portal of the EMA (European Medicines Agency) to launch SARA-31, the first phase 3 study in sarcopenia.
The launch of the Phase 3 program follows the encouraging results obtained with the SARA-INT phase 2b study and interactions with health authorities in 2022. Based on the phase 2b results and agency feedback, Biophytis is starting its phase 3 program by filing the authorization request for the first phase 3 (SARA-31) in Europe.